Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
WEST LAFAYETTE, Ind., Feb. 24, 2016 -- Endocyte, Inc., (NASDAQ:ECYT) announced today that the company will host a conference call on Wednesday, Mar. 2, at 4:30 p.m. EST to discuss its fourth quarter and full year financial results and provide an operational update.
Investors and the general public are invited to listen to a live webcast of the call, which can be accessed in the Investors & News section of the Company’s website at www.endocyte.com or by dialing (877) 845-0711 (U.S./Canada) or (760) 298-5081 (International).
The webcast will be recorded and available on the Company’s website for one week following the call.
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer and other serious diseases. Endocyte uses its proprietary drug conjugation technology to create novel SMDCs and companion imaging agents for personalized targeted therapies. The company’s SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. For additional information, please visit Endocyte’s website at www.endocyte.com.
Contacts: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected]
